BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai S, Hu X, Chen R, Zhang Y. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma. Front Genet 2021;12:657051. [PMID: 34178028 DOI: 10.3389/fgene.2021.657051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng T, Shan G, Yang H, Gu J, Lu C, Xu F, Ge D. Development of a ferroptosis-based model to predict prognosis, tumor microenvironment, and drug response for lung adenocarcinoma with weighted genes co-expression network analysis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1072589] [Reference Citation Analysis]
2 Li Q, Xiao X, Chen B, Song G, Zeng K, Li B, Miao J, Liu C, Luan Y, Liu B. A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. Front Oncol 2022;12:964838. [DOI: 10.3389/fonc.2022.964838] [Reference Citation Analysis]
3 Wu P, Shi J, Wang Z, Sun W, Zhang H. Evaluate the immune-related eRNA models and signature score to predict the response to immunotherapy in thyroid carcinoma. Cancer Cell Int 2022;22:307. [PMID: 36217201 DOI: 10.1186/s12935-022-02722-8] [Reference Citation Analysis]
4 Panahi-Moghadam S, Hassani S, Farivar S, Vakhshiteh F. Emerging Role of Enhancer RNAs as Potential Diagnostic and Prognostic Biomarkers in Cancer. Noncoding RNA 2022;8:66. [PMID: 36287118 DOI: 10.3390/ncrna8050066] [Reference Citation Analysis]
5 Xu Y, Zou X, Mei J, Gu Y. The Risk Correlation between N7-Methylguanosine Modification-Related lncRNAs and Survival Prognosis of Oral Squamous Cell Carcinoma Based on Comprehensive Bioinformatics Analysis. Applied Bionics and Biomechanics 2022;2022:1-11. [DOI: 10.1155/2022/1666792] [Reference Citation Analysis]
6 Zhou Z, Wang Z, Gao J, Lin Z, Wang Y, Shan P, Li M, Zhou T, Li P. Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. Mol Ther Oncolytics 2022;25:98-120. [PMID: 35506150 DOI: 10.1016/j.omto.2022.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiang Z, Long J, Deng K, Zheng Y, Chen M. eRNAs Identify Immune Microenvironment Patterns and Provide a Novel Prognostic Tool in Acute Myeloid Leukemia. Front Mol Biosci 2022;9:877117. [DOI: 10.3389/fmolb.2022.877117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhu J, Huang Q, Liu S, Peng X, Xue J, Feng T, Huang W, Chen Z, Lai K, Ji Y, Wang M, Yuan R. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma. Front Immunol 2022;13:856186. [PMID: 35479067 DOI: 10.3389/fimmu.2022.856186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ye T, Li LL, Peng XM, Li Q. CYP1B1-AS1 Is a Novel Biomarker in Glioblastoma by Comprehensive Analysis. Dis Markers 2021;2021:8565943. [PMID: 35003394 DOI: 10.1155/2021/8565943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]